Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Engineering antigen-driven co-stimulation and T helper cell activity into TCR-T cells with CD8-41BB fusion receptors enhances anti-tumor activity

Ivy Dutta Justin Oh Liz Cam Allie Luther Palak Sharma Ishina Balwani James Peter Dai Liu Ian C. Miller James R. Bowen Lekshmi Maya Jingyu Peng Eleni Stampouloglou Qing-Zhan Zhang Yoko Kosaka J. Coy Jessica S. Mulkey Evan F. Lind Eliana Ruggiero C. Bonini Laura Sepp-Lorenzino B. Schultes A. Prodeus
Jul 2026 · bioRxiv · 0 citations · 2 references
Biology

TL;DR

WT1-TCR-T cells co-expressing CD8-41BB receptors were able to completely regress established cell line-derived ovarian tumors, showed robust in vivo expansion and persistence, and provided long-term protection from tumor rechallenge, suggesting this platform can be a universal approach for enhancing the therapeutic potential of TCR-based cell therapies.

DOI Semantic Scholar
View source

Similar papers

Open access Sep 2026

CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy

Background T cell receptor (TCR)-engineered T cells target antigens presented on major histocompatibility complex (MHC) class I molecules. MHC class I expression is often low in childhood tumors such as neuroblastoma but can be stimulated by interferon gamma (IFNγ). Chimeric antigen receptor (CAR) T cell effector funct...

Alice Vitali, Jennie Padlo, Carlotta Caramel et al. · 0 citations
Open access Aug 2026

Engineering T cells in vivo to express a synthetic cytokine receptor enables preferential expansion and enrichment of anti-CD22 CAR T cells.

Preclinical studies are described demonstrating that UB-VV400 generates anti-CD22 CAR T cells that kill CD22-expressing B cells and tumor cells in vitro and in vivo, and that engagement of RACR results in the selective expansion and enrichment of CAR T cells in vivo leading to complete tumor clearance and B cell deplet...

Travis J. Friesen, Alyssa Sheih, Nikole Perdue et al. · 0 citations
Jul 2026

Nanoscale artificial antigen presenting cells to expand human antigen-specific cytotoxic CD4 T cells for immunotherapy 2258982

The data show that nanoscale aAPCs reliably expand functional antigen-specific CD4 T cells from human PBMCs, providing both mechanistic insight into cytotoxic CD4 biology and a translational foundation for antigen-specific cell immunotherapy.

Si-Sim Kang, Mu-Qing Zhang, Shuyi Li et al. · 0 citations
Open access Aug 2026

Tumor-specific CD4 T cells cooperate with myeloid cells to remodel the pancreatic tumor microenvironment and enable effective immunotherapy

T tumor-specific CD4 T cells are central mediators of effective immunotherapy in solid tumors, and human immunotherapy transcriptomics shows conserved Th1 programming and Treg destabilization as a feature of response.

Eduardo Cruz-Hinojoza, Zoe C. Schmiechen, Sindri M. Bonner et al. · 0 citations
Review Open access Jul 2026

Activity in vivo of in vitro expanded and adoptively transferred antigen-specific CD8+ T cells against neoepitopes that mediate tumor rejection 2306826

Methods of expansion in vitro of CD8+ T cells against neoepitope-specific CD8+ T cells against neoepitopes PDPRMUT, C3MUT and Ccdc65cMUT, all of which mediate tumor rejection of BALB/c Meth A fibrosarcoma are developed and characterized.

Han-Ning Cheng, Pramod K. Srivastava · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.